{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,3]],"date-time":"2026-11-03T04:44:20Z","timestamp":1793681060750,"version":"4.5.1"},"reference-count":48,"publisher":"Elsevier BV","issue":"8","license":[{"start":{"date-parts":[[2013,4,1]],"date-time":"2013-04-01T00:00:00Z","timestamp":1364774400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Biological Psychiatry"],"published-print":{"date-parts":[[2013,4]]},"DOI":"10.1016\/j.biopsych.2012.10.020","type":"journal-article","created":{"date-parts":[[2012,12,10]],"date-time":"2012-12-10T21:04:58Z","timestamp":1355173498000},"page":"706-713","source":"Crossref","is-referenced-by-count":293,"title":["Extending the Treatment Options in Alcohol Dependence: A Randomized Controlled Study of As-Needed Nalmefene"],"prefix":"10.1016","volume":"73","author":[{"given":"Karl","family":"Mann","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna","family":"Bladstr\u00f6m","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lars","family":"Torup","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antoni","family":"Gual","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wim","family":"van den Brink","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.biopsych.2012.10.020_bib1","doi-asserted-by":"crossref","first-page":"655","DOI":"10.1016\/j.euroneuro.2011.07.018","article-title":"The size and burden of mental disorders and other disorders of the brain in Europe 2010","volume":"21","author":"Wittchen","year":"2011","journal-title":"Eur Neuropsychopharmacol"},{"key":"10.1016\/j.biopsych.2012.10.020_bib2","doi-asserted-by":"crossref","first-page":"2003","DOI":"10.1001\/jama.295.17.2003","article-title":"Combined pharmacotherapies and behavioral interventions for alcohol dependence: The COMBINE study: a randomized controlled trial","volume":"295","author":"Anton","year":"2006","journal-title":"JAMA"},{"key":"10.1016\/j.biopsych.2012.10.020_bib3","doi-asserted-by":"crossref","first-page":"492","DOI":"10.1016\/S0140-6736(09)60009-X","article-title":"Alcohol-use disorders","volume":"373","author":"Schuckit","year":"2009","journal-title":"Lancet"},{"key":"10.1016\/j.biopsych.2012.10.020_bib4","first-page":"858","article-title":"The treatment gap in mental health care","volume":"82","author":"Kohn","year":"2004","journal-title":"Bull World Health Organ"},{"key":"10.1016\/j.biopsych.2012.10.020_bib5","doi-asserted-by":"crossref","first-page":"211","DOI":"10.15288\/jsa.2001.62.211","article-title":"How effective is alcoholism treatment in the United States?","volume":"62","author":"Miller","year":"2001","journal-title":"J Stud Alcohol"},{"key":"10.1016\/j.biopsych.2012.10.020_bib6","doi-asserted-by":"crossref","first-page":"570","DOI":"10.1016\/j.addbeh.2010.12.021","article-title":"Guidelines for allocating outpatient alcohol abusers to levels of care: Predictive validity","volume":"36","author":"Merkx","year":"2011","journal-title":"Addict Behav"},{"key":"10.1016\/j.biopsych.2012.10.020_bib7","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1177\/0269881103174017","article-title":"Does acamprosate improve reduction of drinking as well as aiding abstinence?","volume":"17","author":"Chick","year":"2003","journal-title":"J Psychopharmacol"},{"key":"10.1016\/j.biopsych.2012.10.020_bib8","unstructured":"Slattery J, Chick J, Cochrane M, Craig J, Godfrey C, Macpherson K, et al. (2002): Health technology assessment of prevention of relapse in alcohol dependence. Consultation Assessment Report. Glasgow, UK: 1\u2013295"},{"key":"10.1016\/j.biopsych.2012.10.020_bib9","doi-asserted-by":"crossref","first-page":"1645","DOI":"10.1097\/01.ALC.0000090144.99832.19","article-title":"Treatment of alcohol abuse: An evidence-based review","volume":"27","author":"Berglund","year":"2003","journal-title":"Alcohol Clin Exp Res"},{"key":"10.1016\/j.biopsych.2012.10.020_bib10","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1097\/01.ALC.0000108656.81563.05","article-title":"The efficacy of acamprosate in the maintenance of abstinence in alcohol-dependent individuals: Results of a meta-analysis","volume":"28","author":"Mann","year":"2004","journal-title":"Alcohol Clin Exp Res"},{"key":"10.1016\/j.biopsych.2012.10.020_bib11","unstructured":"European Medicines Agency (EMEA) (2010): Guideline on the development of medicinal products for the treatment of alcohol dependence. EMEA\/CHMP\/EWP\/20097\/2008. Available at: http:\/\/www.ema.europa.eu\/docs\/en_GB\/document_library\/Scientific_guideline\/2010\/03\/WC500074898.pdf."},{"key":"10.1016\/j.biopsych.2012.10.020_bib12","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1016\/j.jsat.2006.09.008","article-title":"Reduction in heavy drinking as a treatment outcome in alcohol dependence","volume":"33","author":"Gastfriend","year":"2007","journal-title":"J Subst Abuse Treat"},{"key":"10.1016\/j.biopsych.2012.10.020_bib13","doi-asserted-by":"crossref","first-page":"670","DOI":"10.1038\/nrn3110","article-title":"Pharmacogenetic approaches to the treatment of alcohol addiction","volume":"12","author":"Heilig","year":"2011","journal-title":"Nat Rev Neurosci"},{"issue":"suppl 2","key":"10.1016\/j.biopsych.2012.10.020_bib14","doi-asserted-by":"crossref","first-page":"S116","DOI":"10.1007\/s00406-010-0153-7","article-title":"Individualised treatment in alcohol-dependent patients","volume":"260","author":"Mann","year":"2010","journal-title":"Eur Arch Psychiatry Clin Neurosci"},{"key":"10.1016\/j.biopsych.2012.10.020_bib15","doi-asserted-by":"crossref","first-page":"402","DOI":"10.1038\/npp.2011.182","article-title":"The Alcohol Clinical Trials Initiative (ACTIVE): Purpose and goals for assessing important and salient issues for medications development in alcohol use disorders","volume":"37","author":"Anton","year":"2012","journal-title":"Neuropsychopharmacology"},{"key":"10.1016\/j.biopsych.2012.10.020_bib16","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1016\/0005-7967(76)90013-9","article-title":"Second year treatment outcome of alcoholics treated by individualized behavior therapy: Results","volume":"14","author":"Sobell","year":"1976","journal-title":"Behav Res Ther"},{"key":"10.1016\/j.biopsych.2012.10.020_bib17","doi-asserted-by":"crossref","first-page":"1149","DOI":"10.1111\/j.1360-0443.1995.tb01077.x","article-title":"Controlled drinking after 25 years: How important was the great debate?","volume":"90","author":"Sobell","year":"1995","journal-title":"Addiction"},{"key":"10.1016\/j.biopsych.2012.10.020_bib18","doi-asserted-by":"crossref","first-page":"586","DOI":"10.1093\/alcalc\/agr083","article-title":"Is controlled drinking an acceptable goal in the treatment of alcohol dependence? A survey of French alcohol specialists","volume":"46","author":"Luquiens","year":"2011","journal-title":"Alcohol Alcohol"},{"key":"10.1016\/j.biopsych.2012.10.020_bib19","unstructured":"National Institute for Health and Clinical Excellence (NICE) (2011): NICE clinical guideline 115. Alcohol use disorders: Diagnosis, assessment and management of harmful drinking and alcohol dependence. Available at: http:\/\/publications.nice.org.uk\/alcohol-use-disorders-diagnosis-assessment-and-management-of-harmful-drinking-and-alcohol-cg115."},{"key":"10.1016\/j.biopsych.2012.10.020_bib20","doi-asserted-by":"crossref","first-page":"1641","DOI":"10.1001\/jama.298.14.1641","article-title":"Topiramate for treating alcohol dependence: A randomized controlled trial","volume":"298","author":"Johnson","year":"2007","journal-title":"JAMA"},{"issue":"suppl 1","key":"10.1016\/j.biopsych.2012.10.020_bib21","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1111\/j.1360-0443.2010.03326.x","article-title":"Epidemiology and alcohol policy in Europe","volume":"106","author":"Rehm","year":"2011","journal-title":"Addiction"},{"key":"10.1016\/j.biopsych.2012.10.020_bib22","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1093\/alcalc\/agp096","article-title":"Initial preference for drinking goal in the treatment of alcohol problems: I. Baseline differences between abstinence and non-abstinence groups","volume":"45","author":"Heather","year":"2010","journal-title":"Alcohol Alcohol"},{"key":"10.1016\/j.biopsych.2012.10.020_bib23","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1093\/alcalc\/agq005","article-title":"Initial preference for drinking goal in the treatment of alcohol problems: II. Treatment outcomes","volume":"45","author":"Adamson","year":"2010","journal-title":"Alcohol Alcohol"},{"key":"10.1016\/j.biopsych.2012.10.020_bib24","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1016\/S0306-4603(96)00013-5","article-title":"Drinking goal selection in behavioral self-management treatment of chronic alcoholics","volume":"22","author":"Hodgins","year":"1997","journal-title":"Addict Behav"},{"key":"10.1016\/j.biopsych.2012.10.020_bib25","doi-asserted-by":"crossref","first-page":"2254","DOI":"10.1038\/sj.npp.1300811","article-title":"Nalmefene induced elevation in serum prolactin in normal human volunteers: Partial kappa opioid agonist activity?","volume":"30","author":"Bart","year":"2005","journal-title":"Neuropsychopharmacology"},{"key":"10.1016\/j.biopsych.2012.10.020_bib26","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1007\/s002130050169","article-title":"Endogenous opioid systems and alcohol addiction","volume":"129","author":"Herz","year":"1997","journal-title":"Psychopharmacology"},{"key":"10.1016\/j.biopsych.2012.10.020_bib27","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1007\/7854_2011_129","article-title":"Theoretical frameworks and mechanistic aspects of alcohol addiction: Alcohol addiction as a reward deficit disorder","volume":"13","author":"Koob","year":"2013","journal-title":"Curr Top Behav Neurosci"},{"key":"10.1016\/j.biopsych.2012.10.020_bib28","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1016\/j.neuropharm.2011.02.012","article-title":"Kappa-opioid receptors are implicated in the increased potency of intra-accumbens nalmefene in ethanol-dependent rats","volume":"61","author":"Nealey","year":"2011","journal-title":"Neuropharmacology"},{"key":"10.1016\/j.biopsych.2012.10.020_bib29","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1097\/01.jcp.0000130555.63254.73","article-title":"A multi-site dose ranging study of nalmefene in the treatment of alcohol dependence","volume":"24","author":"Anton","year":"2004","journal-title":"J Clin Psychopharmacol"},{"key":"10.1016\/j.biopsych.2012.10.020_bib30","doi-asserted-by":"crossref","first-page":"1162","DOI":"10.1111\/j.1530-0277.1994.tb00098.x","article-title":"A double-blind, placebo-controlled pilot study to evaluate the efficacy and safety of oral nalmefene HCl for alcohol dependence","volume":"18","author":"Mason","year":"1994","journal-title":"Alcohol Clin Exp Res"},{"key":"10.1016\/j.biopsych.2012.10.020_bib31","doi-asserted-by":"crossref","first-page":"719","DOI":"10.1001\/archpsyc.56.8.719","article-title":"A double-blind, placebo-controlled study of oral nalmefene for alcohol dependence","volume":"56","author":"Mason","year":"1999","journal-title":"Arch Gen Psychiatry"},{"key":"10.1016\/j.biopsych.2012.10.020_bib32","doi-asserted-by":"crossref","first-page":"1179","DOI":"10.1111\/j.1530-0277.2007.00401.x","article-title":"Targeted nalmefene with simple medical management in the treatment of heavy drinkers: A randomized double-blind placebo-controlled multicenter study","volume":"31","author":"Karhuvaara","year":"2007","journal-title":"Alcohol Clin Exp Res"},{"key":"10.1016\/j.biopsych.2012.10.020_bib33","series-title":"Diagnostic and Statistical Manual of Mental Disorders. 4th ed., Text Revision (DSM-IV-TR)","author":"American Psychiatric Association (APA)","year":"2000"},{"key":"10.1016\/j.biopsych.2012.10.020_bib34","doi-asserted-by":"crossref","first-page":"224","DOI":"10.1016\/S0924-9338(97)83296-8","article-title":"The Mini International Neuropsychiatric Interview (MINI). A short diagnostic structured interview: Reliability and validity according to the CIDI","volume":"12","author":"Lecrubier","year":"1997","journal-title":"Eur Psychiatry"},{"key":"10.1016\/j.biopsych.2012.10.020_bib35","series-title":"International Guide for Monitoring Alcohol Consumption and Related Harm","author":"World Health Organization (WHO)","year":"2000"},{"key":"10.1016\/j.biopsych.2012.10.020_bib36","doi-asserted-by":"crossref","first-page":"1353","DOI":"10.1111\/j.1360-0443.1989.tb00737.x","article-title":"Assessment of alcohol withdrawal: The revised clinical institute withdrawal assessment for alcohol scale (CIWA-Ar)","volume":"84","author":"Sullivan","year":"1989","journal-title":"Br J Addict"},{"key":"10.1016\/j.biopsych.2012.10.020_bib37","series-title":"Measuring Alcohol Consumption: Psychosocial and Biological Methods","first-page":"41","article-title":"Timeline follow-back: A technique for assessing self-reported ethanol consumption","author":"Sobell","year":"1992"},{"key":"10.1016\/j.biopsych.2012.10.020_bib38","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1097\/00131746-200603000-00003","article-title":"The BRENDA Model: Integrating psychosocial treatment and pharmacotherapy for the treatment of alcohol use disorders","volume":"12","author":"Starosta","year":"2006","journal-title":"J Psychiatr Pract"},{"key":"10.1016\/j.biopsych.2012.10.020_bib39","series-title":"ECDEU Assessment Manual for Psychopharmacology. Publication No 76\u2013338","year":"1976"},{"key":"10.1016\/j.biopsych.2012.10.020_bib40","series-title":"Alcohol Dependence Scale: Users Guide","author":"Skinner","year":"1984"},{"key":"10.1016\/j.biopsych.2012.10.020_bib41","series-title":"The Drinker Inventory of Consequences (DrInC): An Instrument for Assessing Adverse Consequences of Alcohol Abuse. Project MATCH Monograph Series","author":"Miller","year":"1995"},{"key":"10.1016\/j.biopsych.2012.10.020_bib42","first-page":"44","article-title":"Helping patients who drink too much: An evidence-based guide for primary care clinicians","volume":"80","author":"Willenbring","year":"2009","journal-title":"Am Fam Physician"},{"key":"10.1016\/j.biopsych.2012.10.020_bib43","doi-asserted-by":"crossref","first-page":"817","DOI":"10.1111\/j.1360-0443.2010.02899.x","article-title":"The relation between different dimensions of alcohol consumption and burden of disease: An overview","volume":"105","author":"Rehm","year":"2010","journal-title":"Addiction"},{"key":"10.1016\/j.biopsych.2012.10.020_bib44","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1093\/alcalc\/agm136","article-title":"A randomized, multicentre, open-label, comparative trial of disulfiram, naltrexone and acamprosate in the treatment of alcohol dependence","volume":"43","author":"Laaksonen","year":"2008","journal-title":"Alcohol Alcohol"},{"key":"10.1016\/j.biopsych.2012.10.020_bib45","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1016\/S0306-4603(96)00064-0","article-title":"Targeted naltrexone treatment of early problem drinkers","volume":"22","author":"Kranzler","year":"1997","journal-title":"Addict Behav"},{"key":"10.1016\/j.biopsych.2012.10.020_bib46","doi-asserted-by":"crossref","first-page":"294","DOI":"10.1097\/01.jcp.0000084030.22282.6d","article-title":"Targeted naltrexone for early problem drinkers","volume":"23","author":"Kranzler","year":"2003","journal-title":"J Clin Psychopharmacol"},{"key":"10.1016\/j.biopsych.2012.10.020_bib47","doi-asserted-by":"crossref","first-page":"350","DOI":"10.1097\/JCP.0b013e3181ac5213","article-title":"Targeted naltrexone for problem drinkers","volume":"29","author":"Kranzler","year":"2009","journal-title":"J Clin Psychopharmacol"},{"key":"10.1016\/j.biopsych.2012.10.020_bib48","doi-asserted-by":"crossref","first-page":"1300","DOI":"10.1111\/j.1530-0277.1998.tb03912.x","article-title":"Matching alcoholism treatments to client heterogeneity: Project MATCH three-year drinking outcomes","volume":"22","author":"Project MATCH Research Group","year":"1998","journal-title":"Alcohol Clin Exp Res"}],"container-title":["Biological Psychiatry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0006322312009420?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0006322312009420?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2018,10,20]],"date-time":"2018-10-20T04:51:26Z","timestamp":1540011086000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0006322312009420"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,4]]},"references-count":48,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2013,4]]}},"alternative-id":["S0006322312009420"],"URL":"https:\/\/doi.org\/10.1016\/j.biopsych.2012.10.020","relation":{"has-review":[{"id-type":"doi","id":"10.3410\/f.717976752.793469758","asserted-by":"object"},{"id-type":"doi","id":"10.3410\/f.717976752.793479317","asserted-by":"object"},{"id-type":"doi","id":"10.3410\/f.717976752.793471587","asserted-by":"object"},{"id-type":"doi","id":"10.3410\/f.717976752.793470512","asserted-by":"object"}]},"ISSN":["0006-3223"],"issn-type":[{"value":"0006-3223","type":"print"}],"subject":[],"published":{"date-parts":[[2013,4]]}}}